PURPOSE: Postoperative cholelithiasis (CL) is a latent complication of bariatric surgery. The aim of this study was to evaluate the role of ursodeoxycholic acid (UDCA) in the prevention of CL after laparoscopic sleeve gastrectomy (LSG). METHODS: This was a retrospective analysis of the prospectively collected data of patients with morbid obesity who underwent LSG. Patients were subdivided into two groups: Group I, which did not receive prophylactic treatment with UCDA after LSG; and Group II, which received UCDA therapy for 6 months after LSG. Patients' characteristics, operation duration, weight loss data, and incidence of CL at 6 and 12 months postoperatively were collected. RESULTS: A total of 406 patients (124 males, 282 females) with a mean age of 32.1 ± 9.4 years were included. The mean baseline body mass index (BMI) was 50.1 ± 8.3 kg/m2. Group I comprised 159 patients, and Group II comprised 247 patients. The two groups showed comparable demographics, % excess weight loss (EWL), and decrease in BMI at 6 and 12 months after LSG. Eight patients (5%) developed CL in Group I, whereas no patients in Group II did (P = 0.0005). Preoperative dyslipidemia and rapid loss of excess weight within the first 3 months after LSG were the risk factors that significantly predicted CL postoperatively. CONCLUSION: The use of UCDA effectively reduced the incidence of CL after LSG in patients with morbid obesity. Dyslipidemia and rapid EWL in the first 3 months after LSG significantly predisposed patients to postoperative CL.
PURPOSE:Postoperative cholelithiasis (CL) is a latent complication of bariatric surgery. The aim of this study was to evaluate the role of ursodeoxycholic acid (UDCA) in the prevention of CL after laparoscopic sleeve gastrectomy (LSG). METHODS: This was a retrospective analysis of the prospectively collected data of patients with morbid obesity who underwent LSG. Patients were subdivided into two groups: Group I, which did not receive prophylactic treatment with UCDA after LSG; and Group II, which received UCDA therapy for 6 months after LSG. Patients' characteristics, operation duration, weight loss data, and incidence of CL at 6 and 12 months postoperatively were collected. RESULTS: A total of 406 patients (124 males, 282 females) with a mean age of 32.1 ± 9.4 years were included. The mean baseline body mass index (BMI) was 50.1 ± 8.3 kg/m2. Group I comprised 159 patients, and Group II comprised 247 patients. The two groups showed comparable demographics, % excess weight loss (EWL), and decrease in BMI at 6 and 12 months after LSG. Eight patients (5%) developed CL in Group I, whereas no patients in Group II did (P = 0.0005). Preoperative dyslipidemia and rapid loss of excess weight within the first 3 months after LSG were the risk factors that significantly predicted CL postoperatively. CONCLUSION: The use of UCDA effectively reduced the incidence of CL after LSG in patients with morbid obesity. Dyslipidemia and rapid EWL in the first 3 months after LSG significantly predisposed patients to postoperative CL.
Authors: Joseph A Caruana; Marc N McCabe; Audrey D Smith; Daniel Sette Camara; Michele A Mercer; John A Gillespie Journal: Surg Obes Relat Dis Date: 2005 Nov-Dec Impact factor: 4.734
Authors: Victor B Tsirline; Zeid M Keilani; Sofiane El Djouzi; Ryan C Phillips; Timothy S Kuwada; Keith Gersin; Connie Simms; Dimitrios Stefanidis Journal: Surg Obes Relat Dis Date: 2013-10-25 Impact factor: 4.734
Authors: H J Sugerman; W H Brewer; M L Shiffman; R E Brolin; M A Fobi; J H Linner; K G MacDonald; A M MacGregor; L F Martin; J C Oram-Smith Journal: Am J Surg Date: 1995-01 Impact factor: 2.565
Authors: K R Maurer; J E Everhart; T M Ezzati; R S Johannes; W C Knowler; D L Larson; R Sanders; T H Shawker; H P Roth Journal: Gastroenterology Date: 1989-02 Impact factor: 22.682
Authors: R Vilallonga; J L Pereira-Cunill; S Morales-Conde; I Alarcón; I Breton; E Domínguez-Adame; J V Ferrer; A Garcia Ruiz-de-Gordejuela; A Goday; A Lecube; E Martín García-Almenta; M Á Rubio; F J Tinahones; P P García-Luna Journal: Obes Surg Date: 2019-12 Impact factor: 4.129
Authors: Sylke Haal; Maimoena S S Guman; Sjoerd Bruin; Ruben Schouten; Ruben N van Veen; Paul Fockens; Marcel G W Dijkgraaf; Barbara A Hutten; Victor E A Gerdes; Rogier P Voermans Journal: Obes Surg Date: 2022-02-10 Impact factor: 4.129